Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
National Institutes of Health · Kyoto University · +2 more institutions
Abstract
Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA single-strand breaks (SSB). However, the mechanism of action of PARP inhibitors with regard to their effects in cancer cells is not fully understood. In this study, we show that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA. Trapped PARP-DNA complexes were more cytotoxic than unrepaired SSBs caused by PARP inactivation, arguing that PARP inhibitors act in part as poisons that trap PARP enzyme on DNA. Moreover, the potency in trapping PARP differed markedly among inhibitors with niraparib (MK-4827) > olaparib (AZD-2281) >> veliparib (ABT-888), a pattern not…
Citation impact
- FWCI
- 34.20
- Percentile
- 100%
- References
- 50
Authors
9- JMJunko Murai
National Institutes of Health, Kyoto University, National Cancer Institute, Center for Cancer Research
- SNShar-yin N. Huang
National Institutes of Health, Kyoto University, National Cancer Institute, Center for Cancer Research
- BBBenu Brata Das
National Institutes of Health, Kyoto University, National Cancer Institute, Center for Cancer Research
- ARAmèlie Renaud
National Institutes of Health, Kyoto University, National Cancer Institute, Center for Cancer Research
- YZYiping Zhang
National Institutes of Health, Kyoto University, National Cancer Institute, Center for Cancer Research
Topics & keywords
- Veliparib
- Olaparib
- PARP1
- Poly ADP ribose polymerase
- DNA repair
- PARP inhibitor
- DNA damage
- Homologous recombination
- Good health and well-being